Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (MDT) is a global leader in medical technology, developing innovative healthcare solutions that address chronic diseases and complex conditions. This dedicated news hub provides investors and professionals with timely updates on the company's strategic initiatives, regulatory milestones, and technological breakthroughs.
Access authoritative information spanning earnings announcements, product approvals, partnership developments, and clinical trial outcomes. Our curated collection ensures you stay informed about MDT's advancements in cardiac care, neuromodulation, diabetes management, and surgical robotics.
Discover press releases detailing regulatory submissions, executive appointments, and global market expansions. Each update is verified for accuracy, offering insights into how Medtronic maintains its position at the forefront of medical innovation while navigating evolving healthcare landscapes.
Bookmark this page for direct access to primary source materials and analysis-free reporting on MDT's operational developments. Regular updates ensure you never miss critical information impacting the medical technology sector.
Medtronic plc (NYSE:MDT) will announce its financial results for the fourth quarter and full fiscal year 2024 on Thursday, May 23, 2024. The company will release summary financial information for the period ending on Friday, April 26, 2024. The results will be discussed in a video webcast at 7:00 a.m. CDT on the same day, with a replay and transcript available within 24 hours. Medtronic plans to report fiscal year 2025 results on various dates later in the year.
In a recent press release by Medtronic, Chief Scientific and Medical Officer Laura Mauri discusses the intersection of healthcare and technology in achieving longevity. While many Americans aspire to live past 90, the survey reveals a preference for a shorter, healthier life. Despite belief in healthcare technology, engagement in preventative measures remains low. Medtronic aims to bridge this gap by providing innovative solutions that enhance patient outcomes and experiences. By sharing four actions under the acronym T.E.C.H., individuals are encouraged to take charge of their health and well-being.
Medtronic's groundbreaking SMART clinical trial focusing on women with aortic stenosis marks a pivotal moment in women's health. The study compared Medtronic's Evolut transcatheter aortic heart valve system with Edwards Sapien, revealing superior performance of the Evolut system. Female-specific data from the trial sheds light on gender inequities in heart health care, emphasizing the need to address underrepresentation of women in clinical trials.
FAQ
What is the current stock price of Medtronic (MDT)?
What is the market cap of Medtronic (MDT)?
